Cargando…
Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
PURPOSE: Patients with HER2-positive (HER2(+)) metastatic breast cancer (MBC) have poor prognoses. Pyrotinib has shown promising antitumor activity in MBC to improve progression-free survival (PFS). However, findings based on real-world data to analyze whether pyrotinib affects overall survival (OS)...
Autores principales: | Anwar, Munawar, Chen, Qitong, Ouyang, Dengjie, Wang, Shouman, Xie, Ning, Ouyang, Quchang, Fan, Peizhi, Qian, Liyuan, Chen, Gannong, Zhou, Enxiang, Guo, Lei, Gu, Xiaowen, Ding, Boning, Yang, Xiaohong, Liu, Liping, Deng, Chao, Xiao, Zhi, Li, Jing, Wang, Yunqi, Zeng, Shan, Hu, Jinhui, Zhou, Wei, Qiu, Bo, Wang, Zhongming, Weng, Jie, Liu, Mingwen, Li, Yi, Tang, Tiegang, Wang, Jianguo, Zhang, Hui, Dai, Bin, Tang, Wuping, Wu, Tao, Xiao, Maoliang, Li, Xiantao, Liu, Hailong, Li, Lai, Yi, Wenjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401483/ https://www.ncbi.nlm.nih.gov/pubmed/34112711 http://dx.doi.org/10.1158/1078-0432.CCR-21-0474 |
Ejemplares similares
-
Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2020) -
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2021) -
Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
por: Xie, Ning, et al.
Publicado: (2021) -
A literature review of the promising future of TROP2: a potential drug therapy target
por: Wen, Ying, et al.
Publicado: (2022) -
The Expression, Functions, Interactions and Prognostic Values of PTPRZ1: A Review and Bioinformatic Analysis
por: Xia, Zhenkun, et al.
Publicado: (2019)